Our ICE COLD-PCR technology preferentially enriches mutant DNA sequences in an excess of wild-type DNA through selective amplification of the mutant DNA. The result is up to a 500-fold increase in sensitivity in identifying mutations with the most precise sequence alteration detection rates available—down to .1% enabling mutation detection testing liquid biopsies. This capability removes the restriction for obtaining a tissue biopsy for genetic testing allowing for a more accurate diagnosis and monitoring of patients currently on therapies.
The ICEme Reagent has a number of specific applications for mutation specific, disease specific and gene specific panels. Customizable panels for specific exons are also available upon request.